Fourth quarter and full year 2022 results

Fourth quarter and full-year 2022 results were reviewed by management during a live audio webcast with the financial community. The presentation was followed by a Q&A session.

(14h00 - 15h30 CET / 8:00 - 9:30am EST)


Paul Hudson

Chief Executive Officer

Jean-Baptiste de Chatillon

Chief Financial Officer

Bill Sibold

Specialty Care

Olivier Charmeil

General Medicines

John Reed


Thomas Triomphe


Julie Van Ongevalle

Consumer Healthcare

Roy Papatheodorou

General Counsel


With ten consecutive quarters of growth, the progress we’ve made in the past three years speaks for itself. As we launch the next phase of our strategy, our continued commitment to investing in the science will be crucial to maintaining a steady-state cadence of first and best in class medicines.

Paul Hudson

Chief Executive Officer, Sanofi


Press release


Q4 and FY 2022 Income statements, cash flow statements, balance sheet

Q4 and FY 2022 net sales by GBU, franchise, geographic region and product

R&D appendix

Download infographic

Q4 2022 Memorandum for modelling purposes


Investor Relations
investor.relations (at) 

More contact information